| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Papers In Press, published online ahead of print November 25, 2005
Physiology Dept., University of Bristol, School of Medical Sciences, Bristol BS8 1TD
Corresponding Author: D.N.Sheppard{at}bristol.ac.uk
The genetic disease cystic fibrosis (CF) is caused by loss of function of the cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel. Two CF mutants, G551D and G1349D, affect equivalent residues in the highly conserved LSGGQ motifs that are essential components of the ATP-binding sites of CFTR. Both mutants disrupt severely CFTR channel gating by decreasing mean burst duration (MBD) and prolonging greatly the interburst interval (IBI). To identify small molecules that rescue the gating defects of G551D- and G1349D-CFTR and understand better how these agents work, we used the patch-clamp technique to study the effects on G551D- and G1349D-CFTR of phloxine B, pyrophosphate (PPi) and 2’-deoxy ATP (2’-dATP), three agents that enhance strongly CFTR channel gating. Phloxine B (5
J. Biol. Chem, 10.1074/jbc.M510576200
Submitted on September 27, 2005
Revised on November 22, 2005
Accepted on November 24, 2005
Differential sensitivity of the CF-associated mutants G551D and G1349D to potentiators of the CFTR Cl- channel
M) potentiated robustly G551D-CFTR Cl- channels by altering both MBD and IBI. In contrast, phloxine B (5 M) decreased the IBI of G1349D-CFTR, but this effect was insufficient to rescue G1349D-CFTR channel gating. PPi (5 mM) potentiated weakly G551D-CFTR and was without effect on the G1349D-CFTR Cl- channel. However, by altering both MBD and IBI, albeit with different efficacies, 2’-dATP (1 mM) potentiated both G551D- and G1349D-CFTR Cl- channels. Using the ATP-driven nucleotide-binding domain dimerization model of CFTR channel gating, we suggest that phloxine B, PPi and 2’-dATP alter channel gating by distinct mechanisms. We conclude that G551D- and G1349D-CFTR have distinct pharmacological profiles and speculate that drug therapy for CF is likely to be mutation-specific.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  T.-Y. Chen and T.-C. Hwang CLC-0 and CFTR: Chloride Channels Evolved From Transporters Physiol Rev, April 1, 2008; 88(2): 351 - 387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Bompadre, M. Li, and T.-C. Hwang Mechanism of G551D-CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Potentiation by a High Affinity ATP Analog J. Biol. Chem., February 29, 2008; 283(9): 5364 - 5369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. S. Scott-Ward, Z. Cai, E. S. Dawson, A. Doherty, A. Carina Da Paula, H. Davidson, D. J. Porteous, B. J. Wainwright, M. D. Amaral, D. N. Sheppard, et al. Chimeric constructs endow the human CFTR Cl channel with the gating behavior of murine CFTR PNAS, October 9, 2007; 104(41): 16365 - 16370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Bompadre, Y. Sohma, M. Li, and T.-C. Hwang G551D and G1349D, Two CF-associated Mutations in the Signature Sequences of CFTR, Exhibit Distinct Gating Defects J. Gen. Physiol., March 26, 2007; 129(4): 285 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Zegarra-Moran, M. Monteverde, L. J. V. Galietta, and O. Moran Functional Analysis of Mutations in the Putative Binding Site for Cystic Fibrosis Transmembrane Conductance Regulator Potentiators: INTERACTION BETWEEN ACTIVATION AND INHIBITION J. Biol. Chem., March 23, 2007; 282(12): 9098 - 9104. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
